TY - JOUR
T1 - Cerebrovascular Events After Continuous-Flow Left Ventricular Assist Devices
AU - Tahsili-Fahadan, Pouya
AU - Curfman, David R.
AU - Davis, Albert A.
AU - Yahyavi-Firouz-Abadi, Noushin
AU - Rivera-Lara, Lucia
AU - Nassif, Michael E.
AU - LaRue, Shane J.
AU - Ewald, Gregory A.
AU - Zazulia, Allyson R.
N1 - Funding Information:
This study was supported, in part, by research funds from the National Institutes of Health (NIH Grant U10 HL110309, Heart Failure Network) and Grant Number UL1 TR000448 R01 HL097036
Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Background: Cerebrovascular events (CVE) are among the most common and serious complications after implantation of continuous-flow left ventricular assist devices (CF-LVAD). We studied the incidence, subtypes, anatomical distribution, and pre- and post-implantation risk factors of CVEs as well as the effect of CVEs on outcomes after CF-LVAD implantation at our institution. Methods: Retrospective analysis of clinical and neuroimaging data of 372 patients with CF-LVAD between May 2005 and December 2013 using standard statistical methods. Results: CVEs occurred in 71 patients (19%), consisting of 35 ischemic (49%), 26 hemorrhagic (37%), and 10 ischemic+hemorrhagic (14%) events. History of coronary artery disease and female gender was associated with higher odds of ischemic CVE (OR 2.84 and 2.5, respectively), and diabetes mellitus was associated with higher odds of hemorrhagic CVE (OR 3.12). While we found a higher rate of ischemic CVEs in patients not taking any antithrombotic medications, no difference was found between patients with ischemic and hemorrhagic CVEs. Occurrence of CVEs was associated with increased mortality (HR 1.62). Heart transplantation was associated with improved survival (HR 0.02). In patients without heart transplantation, occurrence of CVE was associated with decreased survival. Conclusions: LVADs are associated with high rates of CVE, increased mortality, and lower rates of heart transplantation. Further investigations to identify the optimal primary and secondary stroke prevention measures in post-LVAD patients are warranted.
AB - Background: Cerebrovascular events (CVE) are among the most common and serious complications after implantation of continuous-flow left ventricular assist devices (CF-LVAD). We studied the incidence, subtypes, anatomical distribution, and pre- and post-implantation risk factors of CVEs as well as the effect of CVEs on outcomes after CF-LVAD implantation at our institution. Methods: Retrospective analysis of clinical and neuroimaging data of 372 patients with CF-LVAD between May 2005 and December 2013 using standard statistical methods. Results: CVEs occurred in 71 patients (19%), consisting of 35 ischemic (49%), 26 hemorrhagic (37%), and 10 ischemic+hemorrhagic (14%) events. History of coronary artery disease and female gender was associated with higher odds of ischemic CVE (OR 2.84 and 2.5, respectively), and diabetes mellitus was associated with higher odds of hemorrhagic CVE (OR 3.12). While we found a higher rate of ischemic CVEs in patients not taking any antithrombotic medications, no difference was found between patients with ischemic and hemorrhagic CVEs. Occurrence of CVEs was associated with increased mortality (HR 1.62). Heart transplantation was associated with improved survival (HR 0.02). In patients without heart transplantation, occurrence of CVE was associated with decreased survival. Conclusions: LVADs are associated with high rates of CVE, increased mortality, and lower rates of heart transplantation. Further investigations to identify the optimal primary and secondary stroke prevention measures in post-LVAD patients are warranted.
KW - Cardiac transplant
KW - Heart failure
KW - Left ventricular assist device
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=85045136845&partnerID=8YFLogxK
U2 - 10.1007/s12028-018-0531-y
DO - 10.1007/s12028-018-0531-y
M3 - Article
C2 - 29637518
AN - SCOPUS:85045136845
SN - 1541-6933
VL - 29
SP - 225
EP - 232
JO - Neurocritical Care
JF - Neurocritical Care
IS - 2
ER -